KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

<h4>Background</h4>Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating m...

Full description

Bibliographic Details
Main Authors: William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2005-01-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.0020017

Internet

https://doi.org/10.1371/journal.pmed.0020017

Similar Items